Emerging growth factor receptor antagonists for the treatment of advanced melanoma

Sarah E. Fenton, Jeffrey A. Sosman, Sunandana Chandra*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Introduction: Therapy for metastatic melanoma has undergone a rapid transformation over the past 5–10 years. Advances in immunotherapy with checkpoint inhibitors, including both anti-CTLA-4 and anti-PD-1/PD-L1, have led to durable responses in up to 50% of patients. As our understanding of the processes driving the transformation of melanocytes has improved, progress in targeted therapies has also continued. Areas covered: Angiogenesis and the tumor’s dependence on an expanded vascular supply has been a target for novel therapies since the 1970’s, as this tissue is derived from endothelial cells that are genetically stable in adults. A phase II trial studying combined therapy with bevacizumab (an inhibitor of angiogenesis) and ipilimumab found promising results. Other agents such as sorafenib have not been as successful, failing to extend progression free or overall survival in clinical trials. In this paper other targeted growth factor inhibitors will also be discussed. Expert opinion: Ultimately, melanoma may not be vulnerable solely to chemotherapy or targeted therapy, but may be efficaciously treated with immunotherapy due to its high mutational rate resulting in the expression of numerous neo-antigens. Therapies with combinations of agents including growth factor receptor and either other targeted therapies or immunotherapy may be a promising complimentary approach.

Original languageEnglish (US)
Pages (from-to)165-174
Number of pages10
JournalExpert Opinion on Emerging Drugs
Volume22
Issue number2
DOIs
StatePublished - Apr 3 2017

Fingerprint

Growth Factor Receptors
Melanoma
Immunotherapy
Therapeutics
Growth Inhibitors
Angiogenesis Inhibitors
Melanocytes
Expert Testimony
Blood Vessels
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Clinical Trials
Antigens
Drug Therapy
Survival
Neoplasms

Keywords

  • Angiogenesis
  • growth factor receptors
  • melanoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{fbb47d667b8a4f0eac12236810fb27d4,
title = "Emerging growth factor receptor antagonists for the treatment of advanced melanoma",
abstract = "Introduction: Therapy for metastatic melanoma has undergone a rapid transformation over the past 5–10 years. Advances in immunotherapy with checkpoint inhibitors, including both anti-CTLA-4 and anti-PD-1/PD-L1, have led to durable responses in up to 50{\%} of patients. As our understanding of the processes driving the transformation of melanocytes has improved, progress in targeted therapies has also continued. Areas covered: Angiogenesis and the tumor’s dependence on an expanded vascular supply has been a target for novel therapies since the 1970’s, as this tissue is derived from endothelial cells that are genetically stable in adults. A phase II trial studying combined therapy with bevacizumab (an inhibitor of angiogenesis) and ipilimumab found promising results. Other agents such as sorafenib have not been as successful, failing to extend progression free or overall survival in clinical trials. In this paper other targeted growth factor inhibitors will also be discussed. Expert opinion: Ultimately, melanoma may not be vulnerable solely to chemotherapy or targeted therapy, but may be efficaciously treated with immunotherapy due to its high mutational rate resulting in the expression of numerous neo-antigens. Therapies with combinations of agents including growth factor receptor and either other targeted therapies or immunotherapy may be a promising complimentary approach.",
keywords = "Angiogenesis, growth factor receptors, melanoma",
author = "Fenton, {Sarah E.} and Sosman, {Jeffrey A.} and Sunandana Chandra",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/14728214.2017.1336537",
language = "English (US)",
volume = "22",
pages = "165--174",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

Emerging growth factor receptor antagonists for the treatment of advanced melanoma. / Fenton, Sarah E.; Sosman, Jeffrey A.; Chandra, Sunandana.

In: Expert Opinion on Emerging Drugs, Vol. 22, No. 2, 03.04.2017, p. 165-174.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging growth factor receptor antagonists for the treatment of advanced melanoma

AU - Fenton, Sarah E.

AU - Sosman, Jeffrey A.

AU - Chandra, Sunandana

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Therapy for metastatic melanoma has undergone a rapid transformation over the past 5–10 years. Advances in immunotherapy with checkpoint inhibitors, including both anti-CTLA-4 and anti-PD-1/PD-L1, have led to durable responses in up to 50% of patients. As our understanding of the processes driving the transformation of melanocytes has improved, progress in targeted therapies has also continued. Areas covered: Angiogenesis and the tumor’s dependence on an expanded vascular supply has been a target for novel therapies since the 1970’s, as this tissue is derived from endothelial cells that are genetically stable in adults. A phase II trial studying combined therapy with bevacizumab (an inhibitor of angiogenesis) and ipilimumab found promising results. Other agents such as sorafenib have not been as successful, failing to extend progression free or overall survival in clinical trials. In this paper other targeted growth factor inhibitors will also be discussed. Expert opinion: Ultimately, melanoma may not be vulnerable solely to chemotherapy or targeted therapy, but may be efficaciously treated with immunotherapy due to its high mutational rate resulting in the expression of numerous neo-antigens. Therapies with combinations of agents including growth factor receptor and either other targeted therapies or immunotherapy may be a promising complimentary approach.

AB - Introduction: Therapy for metastatic melanoma has undergone a rapid transformation over the past 5–10 years. Advances in immunotherapy with checkpoint inhibitors, including both anti-CTLA-4 and anti-PD-1/PD-L1, have led to durable responses in up to 50% of patients. As our understanding of the processes driving the transformation of melanocytes has improved, progress in targeted therapies has also continued. Areas covered: Angiogenesis and the tumor’s dependence on an expanded vascular supply has been a target for novel therapies since the 1970’s, as this tissue is derived from endothelial cells that are genetically stable in adults. A phase II trial studying combined therapy with bevacizumab (an inhibitor of angiogenesis) and ipilimumab found promising results. Other agents such as sorafenib have not been as successful, failing to extend progression free or overall survival in clinical trials. In this paper other targeted growth factor inhibitors will also be discussed. Expert opinion: Ultimately, melanoma may not be vulnerable solely to chemotherapy or targeted therapy, but may be efficaciously treated with immunotherapy due to its high mutational rate resulting in the expression of numerous neo-antigens. Therapies with combinations of agents including growth factor receptor and either other targeted therapies or immunotherapy may be a promising complimentary approach.

KW - Angiogenesis

KW - growth factor receptors

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=85021095646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021095646&partnerID=8YFLogxK

U2 - 10.1080/14728214.2017.1336537

DO - 10.1080/14728214.2017.1336537

M3 - Review article

C2 - 28562096

AN - SCOPUS:85021095646

VL - 22

SP - 165

EP - 174

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -